Hengrui Medicine subsidiary gets clinical trial approval for muscle relaxant
Jiangsu Hengrui Medicine announced its subsidiary Fujian Shengdi Pharmaceutical obtained approval from the National Medical Products Administration for clinical trials of HRS-2162 injection.
The new-generation muscle relaxant antagonist reverses neuromuscular blockade induced by rocuronium and atracurium. Hengrui Medicine has invested approximately RMB 2,825 million in developing HRS-2162.
The company said no similar products are currently approved in China or internationally.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Jiangsu Hengrui Medicine publishes news
Free account required • Unsubscribe anytime